# Lipocine Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Lipocine Inc.). ## Overview Lipocine Inc. is a U.S.-based biopharmaceutical company developing oral drug-delivery products built on a proprietary lipid-based technology platform. Its programs target hard-to-deliver molecules across testosterone replacement, CNS disorders, liver disease, and women’s health, with TLANDO as its approved commercial product and the rest of the pipeline still in development. ## Products & services • TLANDO oral testosterone replacement therapy • LPCN 1154 oral candidate for postpartum depression • LPCN 2201 oral candidate for major depressive disorder • LPCN 2101 oral candidate for epilepsy • LPCN 1148 for decompensated cirrhosis / hepatic encephalopathy • LPCN 2401 for incretin mimetics use • LPCN 1107 for prevention of pre-term birth - **Commercial product** (25%) — Approved oral testosterone replacement therapy marketed through license partners. - **CNS pipeline** (35%) — Oral neuroactive steroid candidates for postpartum depression, MDD, and epilepsy. - **Liver disease pipeline** (15%) — Programs aimed at decompensated cirrhosis and prevention of overt hepatic encephalopathy. - **Women’s health pipeline** (15%) — Development assets focused on postpartum depression and pre-term birth. - **Licensing and collaboration revenue** (10%) — Upfront, milestone, royalty, and research-support income from partners. - TLANDO oral testosterone replacement therapy - LPCN 1154 oral candidate for postpartum depression - LPCN 2201 oral candidate for major depressive disorder - LPCN 2101 oral candidate for epilepsy - LPCN 1148 for decompensated cirrhosis and hepatic encephalopathy - LPCN 2401 and LPCN 1107 pipeline candidates ## Customers Lipocine sells primarily through licensing and commercialization partners rather than direct hospital or retail channels. Its end customers are patients and prescribing physicians in testosterone replacement, psychiatry, neurology, hepatology, and women’s health, while its direct counterparties are partners that pay license, milestone, royalty, and distribution fees. The company also relies on CROs and contract manufacturers to execute development and supply activities. - **Territory license partners** (primary) — Verity, SPC, Pharmalink, and Aché commercialize TLANDO in their territories and pay milestones/royalties. - **Prescribing physicians** (primary) — Endocrinology, urology, psychiatry, neurology, and hepatology prescribers choose oral options for patients. - **Patients** (primary) — Men and women seeking oral therapies that may improve convenience, adherence, and tolerability. - **Development partners** (secondary) — Potential collaborators for LPCN 1148, LPCN 2401, LPCN 1107, LPCN 1154, LPCN 2201, and LPCN 2101. - **Service providers** (secondary) — CROs and contract manufacturers that support clinical trials and drug production. - License partners commercializing TLANDO in defined territories - Physicians treating testosterone deficiency and related symptoms - Patients needing a differentiated oral TRT option - Potential pharma partners for CNS, liver, and women’s health assets - CROs and contract manufacturers supporting development and supply ## Geography Lipocine is headquartered and primarily operated from Salt Lake City, Utah, with most employees based there. Commercial exposure is global through out-licensing, but current revenue is concentrated in partner territories rather than direct product sales, and the company states it does not expect product sales until approvals outside the U.S. and Canada or FDA approval of additional candidates. Geography matters mainly through regulatory approvals, partner execution, and the ability to expand TLANDO beyond existing licensed territories. - Headquarters and main operations in Salt Lake City, Utah - Most employees work from the Salt Lake City facility - Revenue comes mainly from partner territories via licensing and royalties - No direct product sales yet; commercialization depends on approvals - Future expansion outside current territories is a strategic option ## Strategy Lipocine’s strategy is to use its oral drug-delivery platform to create differentiated products for large unmet medical needs, then advance them through partnerships and licensing. Near term, it is focused on supporting TLANDO commercialization, protecting IP, and progressing key pipeline assets such as LPCN 1154, while preserving liquidity through external financing and collaboration income. - **Support TLANDO partner commercialization** (short-term) — Royalty and milestone income depends on partner execution and market uptake. - **Advance CNS pipeline candidates** (medium-term) — These programs could create future value if clinical data and regulatory progress are positive. - **Pursue partnerships for non-core assets** (medium-term) — Partnerships reduce funding burden and broaden development reach. - **Maintain IP and operating flexibility** (short-term) — Patent protection and lean overhead are critical for a small development-stage biotech. - Leverage oral delivery technology to improve absorption of difficult molecules - Support partner commercialization of TLANDO and collect royalties/milestones - Advance LPCN 1154, LPCN 2201, and LPCN 2101 in CNS indications - Seek partnerships for liver disease and women’s health programs - Protect and expand the intellectual property portfolio - Raise capital through equity, debt, and licensing as needed ## Risks Lipocine remains a development-stage biotech with heavy dependence on clinical outcomes, FDA review, and partner commercialization of TLANDO. It also faces financing risk because future trials, regulatory work, and commercialization support may require additional capital before meaningful product revenue is established. - **Clinical development failure** [high] — Pipeline assets are early stage and depend on positive trial results to support NDA filings and approvals. - **Regulatory approval risk** [high] — The company may not receive FDA approval or approval outside the U.S. for product candidates. - **Partner commercialization risk** [high] — TLANDO revenue depends on third-party licensees successfully marketing and distributing the product. - **Financing risk** [high] — The company expects to need additional capital through equity, debt, or partnering. - **Third-party dependence** [medium] — CROs and contract manufacturers perform substantial trial and manufacturing work. - Clinical trials may be delayed, fail, or produce insufficient efficacy/safety data - FDA approval may not be obtained for pipeline candidates or new territories - TLANDO commercialization depends on licensee execution and market acceptance - Additional capital may be needed before the business becomes self-funding - Reliance on CROs, suppliers, and contract manufacturers creates execution risk - Competition and reimbursement pressure can limit adoption of oral TRT and CNS products ## Accounting Revenue recognition is a key judgment because most income comes from license fees, royalties, milestones, and research support under multiple partner agreements. The company also has meaningful estimates around clinical study costs, outsourced development, and lease accounting for its Salt Lake City facility, while future capital raises and potential impairment assessments could affect reported results. - **Revenue recognition under partner agreements** — Affects reported revenue timing and comparability - **Royalty revenue from TLANDO sales** — Creates quarter-to-quarter revenue volatility - **R&D expense estimation** — Can change operating loss and cash burn - **Lease accounting** — Affects operating expense and balance sheet liabilities - ASC 606 judgment for license, milestone, and royalty revenue timing - Measure of progress under partner agreements affects revenue recognition - Clinical study and outsourced development costs drive R&D expense volatility - Lease accounting for the Salt Lake City headquarters affects operating costs - Future financing and going-concern assumptions may affect disclosures --- *Last updated: 2026-04-28T20:23:09.822574+00:00*